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Abstract 
Streptococcus pyogenes, or Group A Streptococcus (GAS) is responsible for significant 
patient morbidity and mortality in the developing world and within the Australian Indigenous 
population.  GAS is responsible for a variety of diseases such as invasive necrotizing fasciitis 
and toxic shock syndrome, as well as non-invasive diseases, such as pharyngitis, impetigo, 
scarlet fever and otitis media.  However, GAS sequelae such as rheumatic fever and 
rheumatic heart disease are responsible for the highest morbidity.  The 30-valent vaccine 
candidate currently in trials is inappropriately specialised to serotypes present in areas with 
low GAS incidence, such as the United States.  
The difficulty in creation of a suitable vaccine lies in part with the variety of GAS virulence 
factors.  The M protein is a highly abundant, multifunctional immunogenic surface protein 
which confers resistance to phagocytes and complement mediated protection.  As sections of 
the M protein is highly conserved, it has been the focus of vaccination research.  
Furthermore, protein fragments J8 and J14 within the M protein have given encouraging 
results within a mouse model.   
Virus-like particle (VLP) technology offers a promising alternative to existing vaccination 
delivery systems. VLPs are able to induce both cell mediated and humoral immune 
responses.  In this study, the use of a chimeric hepatitis B surface antigen VLP expressing M 
protein epitopes p145, J8 and J14 for use as a dual vaccine against Hepatitis B virus (HBV) 
and GAS is investigated.  Specifically, PCR generated DNA sequences of J8, J14 and p145 
from the M protein of GAS have been cloned into the highly immunogenic ‘a’ determinant 
region of the HBsAg-S VLP and transformed into human embryonic kidney (HEK293T) 
cells.  Expressed recombinant HBsAg-S-GAS-m protein constructs were assayed by ELISA 
to confirm presentation of GAS epitopes. ELISA results showing high titres were obtained 
for VLP:p145 but low titres were obtained for VLP:J8 and VLP:J14.  Further sequencing of 
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plasmid constructs, protein expression and antigenic screening of proteins is required before 
the study can progress to proof-of-concept murine challenge models.  
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Introduction 1 
1.0 Overview of group A streptococcus (GAS) pathogenesis 2 
The bacterium Group A Streptococcus (GAS) (also known as Streptococcus pyogenes) is a 3 
Gram positive coccus which is responsible for a variety of infections and associated 4 
syndromes (Goering et al. 2012).  GAS is prevalent in under-privileged communities such as 5 
the Australian Indigenous population and much of the developing world (Carapetis et al. 6 
2005).  GAS can cause a number of non-invasive diseases such as pharyngitis, impetigo, 7 
pyoderma, scarlet fever and otitis media as well as invasive diseases including necrotising 8 
fasciitis and toxic shock syndrome.  Post-infection sequelae, however account for the highest 9 
global burden of GAS disease and includes rheumatic heart disease (RHD), rheumatic fever 10 
(RF), related endocarditis and stroke, as well as acute post-streptococcal glomerulonephritis 11 
(APSGN) (Henningham et al. 2013).  Whilst research activity in GAS vaccinology has been 12 
ongoing for decades, no approved vaccine has yet become available.   A broad 30-valent 13 
vaccine is under development, however the vaccine focusses on North American and 14 
European specific GAS serotypes which may not address the main serotypes present in the 15 
developing world.  One of the main challenges in vaccine design is the incorporation of the 16 
150 known M protein serotypes to provide cross-serotype protection.  Studies of pharyngeal 17 
infections in South African school children indicate the vaccine coverage will be between 40-18 
59% of isolates recorded (Dale et al. 2011).  This indicates that the 30-valent vaccine is an 19 
ineffective option for a significant proportion of affected individuals in the developing world 20 
(Dale et al. 2011).  Among the many conserved virulence factors which have been explored 21 
for usage in a GAS vaccine, the M protein is a promising target for vaccine research as it is a 22 
highly conserved, abundant surface GAS protein (O'Brien et al. 2002). 23 
 1.1 Distribution and incidence of disease 24 
Currently 18.1 million people worldwide suffer GAS associated infections.  GAS associated 25 
sequelae makes up the majority of cases with 15.6 million individuals currently affected.   26 
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Furthermore, RHD can be fatal and is estimated to cause 233,000 deaths per year (Carapetis 27 
et al. 2005). APSGN affects 472,000 individuals and causes a further 5,000 deaths annually.  28 
Superficial infections occur more frequently, where 6.1 million new cases of pharyngitis arise 29 
every year and 1.1 million individuals currently suffer of pyoderma (Carapetis et al. 2005).  30 
Uncertainty levels and assumptions used in the compilation of GAS data tends towards 31 
underestimation, making the true prevalence likely to be greater than stated. Carapetis et al. 32 
(2005) acknowledges that issues in data collection in developing countries affects quality of 33 
the data.  RHD specific data, however, has a higher level of quality through rigorous data 34 
collection.  RHD has a wide geographical distribution, peaking in the following countries as a 35 
calculated regional prevalence per thousand: Sub-Saharan Africa at 5.7 cases, South-Central 36 
Asia at 2.2 cases, other Asian areas at 0.8 cases, Latin America at 1.3 cases, Middle East and 37 
North Africa at 1.8 cases, Eastern Europe at 1 case, Pacific and Indigenous Australia/New 38 
Zealand at 3.5 cases and China at 0.8 cases (Carapetis et al. 2005).  39 
 1.2 Populations at risk 40 
Populations at risk for GAS disease include children and young adults within the developed 41 
and developing countries.  Less developed countries account for 79% of RHD cases, 95% of 42 
RF cases, 97% of APSGN cases and 97% of invasive GAS cases.  Indigenous Australians 43 
also experience high disease burden (Carapetis et al. 2005).   44 
 1.2.1 Indigenous Australians 45 
As mentioned above, Indigenous Australians are a demographic susceptible to GAS 46 
infection, most commonly suffering superficial skin infections.  Furthermore, APSGN, RF 47 
and RHD are heavily prevalent in the Indigenous population (Carapetis et al. 2005).   48 
Indigenous Australians have the highest annual mortality rate of 30.2 per 100,000 49 
individuals.  This is more than three times as high as the second highest risk population, 50 
Maori New Zealanders at 9.6 per 100,000 individuals (Carapetis et al. 2005). Rural 51 
communities within the Northern Territory and the Kimberley region in Western Australia 52 
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exhibit an annual incidence of RF of between 2-7 cases for every 1000 children between 5-14 53 
years old.  Furthermore, up to 3% of Indigenous people in rural communities have established 54 
RHD in Australia (Carapetis & Currie 1998).   55 
GAS related skin infections such as scabies and streptococcal pyoderma are endemic in 56 
Australian Indigenous communities.  Scabies is a parasitic infection caused by the human itch 57 
mite or Sarcopes scabiei, and is known to spread easily in environments with poor sanitation 58 
and overcrowding (FitzGerald et al. 2014).  There is a distinct link between streptococcal 59 
pyoderma and scabies, as demonstrated by Andrews et al. (2009) (See Figure 1).  For 60 
example, both scabies and streptococcal pyoderma have been found in Indigenous Australian 61 
populations and Alaskan native populations.   Scabies is prevalent in 50% of children and 62 
25% of adults in many remote communities (Carapetis et al. 1997).  Unusually, there is a 63 
distinctly lower rate of GAS throat carriage of between 0-14% in comparison to RHD and 64 
skin infections (Van Buynder et al. 1992).  Household crowding, access to adequate water, 65 
hot weather, humidity and lack of personal hygiene are likely to contribute to a high 66 
prevalence of GAS disease in the Indigenous Australian population (Figure 1) (Munoz et al. 67 
1992).  68 
   69 
 70 
 71 
 72 
 73 
 74 
 75 
 76 
 77 
Figure 1 Outcomes and contributing factors to skin infections in 
Australian Indigenous peoples  
A number of contributing factors can culminate to form a skin infection, which may 
progress to secondary disease states such as acute post-streptococcal glomerulonephritis 
(APSGN) and acute rheumatic fever (ARF) after GAS infection (Andrews et al. 2009).  
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 78 
1.2.2 Paediatric 79 
GAS pharyngitis accounts for 6% of paediatric visits to a medical practitioner, with GAS 80 
cultured from 15-36% of children suffering a sore throat in the US (Linder et al. 2005).  81 
APSGN is also most commonly seen in paediatric patients, equating to 90% of the total 82 
population suffering APSGN.  The skewed distribution towards paediatric patients is 83 
hypothesised to be attributed to the size difference in the glomerular basement membrane 84 
(GBM).   Children and adults have 2-3 nm and 4-4.5 nm GBM sizes, respectively, making it 85 
easier for the immune complex molecule to infect the glomerulus in children rather than 86 
adults (Wiwanitkit 2006).   87 
2.0 The biology of group A streptococcus  88 
Infection with GAS begins with the binding of bacterial surface ligands to extracellular 89 
matrix components or to specific receptors on dermal epithelial cells.  Adhesion is a two-step 90 
process, where an initial weak interaction is engaged with the mucosa to overcome 91 
electrostatic repulsion.  The exchange is finalised through an event conferring tissue 92 
specificity and high-avidity adherence.  To complete the interchange, a number of host 93 
components are known to be involved, such as fibrinogen, fibrin, elastin, vitronectin, laminin, 94 
decorin and heparin sulphate-containing proteoglycans (Moschioni et al. 2010).   In 95 
particular, fibrinogen is known to interact and bind with the highly conserved M protein in 96 
the β–repeat region near the N-terminus of the protein (Carlsson et al. 2005).  97 
As well as cellular adherence, GAS also has the capacity to enter epithelial cells to avoid 98 
early host defences and antibiotics.  This invasive virulence process is possible through 99 
proteins on the cell surface, or invasins such as fibronectin-binding protein and the M protein 100 
(LaPenta et al. 1994).   Further research by Dombek and colleagues (1999) indicates that 101 
invasion initiates through a zipper-like mechanism where host microvilli also play a role.   102 
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2.1 Virulence factors 103 
2.1.1 M protein 104 
M protein is a highly abundant, multifunctional, immunogenic surface protein.  Structurally, 105 
the M protein is an alpha-helical coiled coil dimer anchored to the outer streptococcal cell 106 
wall via the C terminus.  The M protein can be divided up into the hypervariable (A-repeat 107 
region), semi-variable (B-repeat region) and conserved regions (C, D, Pro/Gly and 108 
Hydrophobic regions) (See Figure 2) (McArthur & Walker 2006).  Lancefield GAS 109 
classification is measured through N-terminal nucleotide residues of the emm gene, found in 110 
the aforementioned hyper-variable region.  Specifically, Lancefield typing groups beta 111 
haemolytic bacteria through cell wall carbohydrate composition.  Using the N-terminal 112 
nucleotides as a determinant, more than 150 genotypes of GAS have been found thus far 113 
(Facklam 1997; McGregor et al. 2004).  M proteins are divided into Class I or Class II 114 
dependent upon their reaction with antibodies against the C repeat region of the M protein; 115 
Class I proteins react through the presence of a surface-exposed epitope and Class II does not 116 
react (Bessen et al. 1989).   117 
 118 
 119 
 120 
Figure 2 M protein hypervariable, variable and conserved structures  
The M protein alpha-helical coiled coil structure with anchored domain.  A to C regions of 
the M protein are multi-functional, and the protein can be divided further into conserved, 
variable and hypervariable regions.  Each colour-coded section can interact with the human 
plasma proteins indicated (McArthur & Walker 2006). 
6 
 
M Protein antigenic variation contributes to the range of GAS virulence strategies.  For 121 
example, the ability of M protein to bind to fibrinogen in the B-repeat region interferes with 122 
the complement system and contributes to phagocytic resistance (McArthur & Walker 2006; 123 
Ringdahl et al. 2000).  The M protein provides protection against complement-mediated 124 
opsonisation and phagocytic resistance. Specifically, the M protein binds C4b-binding protein 125 
which inhibits complement activation (Berggård et al. 2001).  The A-repeat region can bind 126 
to IgA, IgG, Factor H, Factor H-like protein 1, C4b binding protein and plasminogen.  The C-127 
repeat region can bind Factor H and human serum albumin, further aiding GAS in phagocytic 128 
evasion (Berggård et al. 2001). 129 
2.1.2 Capsule 130 
The capsule structure contributes considerably to the success of the bacteria.  Acapsular 131 
strains have been shown to have markedly decreased phagocytic resistance, and a 100-fold 132 
decrease in virulence when tested in mice (Wessels et al. 1991).  The GAS capsule consists 133 
of a hyaluronic acid with the degree of encapsulation varying greatly across the serotypes 134 
(See Figure 3).  GAS has been found to up-regulate hyaluronic acid production to structurally 135 
minimise antibody access to bacterial surface protein G-related α2-macroglobulin-binding 136 
protein (GRAB).  This mechanism of evasion contributes to the difficulty in creating a 137 
functional vaccine as it enables GAS to escape recognition by antibodies (Dinkla et al. 2007).   138 
 139 
 140 
 141 
 142 
 143 
 144 
 145 
 146 
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 148 
 149 
 150 
 151 
 152 
 153 
 154 
 155 
 156 
 157 
 158 
 159 
2.1.3 Streptokinase 160 
Streptokinase (SK) is a plasminogen activator and is a secreted GAS virulence factor with 161 
four compact domains.  Secretion of SK is associated with APSGN (Simon et al. 2014).  162 
Specifically, SK binds to plasminogen to induce the structural development of an active site 163 
as well as an enzymatic SK-plasminogen complex.  SK-plasminogen can sequester substrate 164 
plasminogen and convert into the serine protease plasmin.  Control over host plasminogen is 165 
advantageous to overcome host defences by generating unregulated soluble cell-bound 166 
plasmin, which can degrade blood plasma proteins (Simon et al. 2014).  SK is semi-167 
conserved within GAS and can be classified within one of nine polymorphic genotypes where 168 
the main structures such as hydrophobicity are maintained.  SK’s structural variability arises 169 
from a region designated as V1, where it is speculated the genes for nephritis are located 170 
(Malke 1993).  171 
2.1.4 Streptolysin O 172 
Streptolysin O is a bacterial toxin of the cholesterol-dependent cytolysins family (Timmer et 173 
al. 2009).  It is known for its ability to form large pores in cell membranes with membrane 174 
cholesterol facilitation, but it is also thought to have pore-independent functions (Timmer et 175 
al. 2009).   This ability is a crucial defence mechanism as it acts to prevent phagocytosis (Feil 176 
Figure 3 GAS Cross Section 
GAS virulence factors include the M Protein, C5a peptidase and capsule as outer 
structures.  Other virulence factors include streptokinase, streptolysin O, cysteine 
protease SpeB and many others.  Taken from Talaro & Talaro (2002).   
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et al. 2014).  A membrane pore is created in a number of steps.  Firstly, cholesterol-177 
dependent membrane binding is undertaken in a monomeric form.  The pore is completed 178 
through oligomerisation, where ring-like structures are formed on the erythrocyte membranes 179 
(Hugo et al. 1986).   Apoptosis of the phagocyte occurs through caspase-dependent pathways, 180 
promoted by release of cytochrome c and permeabilisation of mitochondrial outer 181 
membranes, leading to decreased cytokine response and greater chance of GAS survival 182 
(Timmer et al. 2009).  183 
2.1.5 C5a Peptidase 184 
C5a peptidase is a ubiquitously expressed surface proteolytic enzyme which acts as an 185 
adhesin and invasin (Cleary et al. 2004).  It is capable of disrupting the complement pathway 186 
via cleavage of chemotaxin C5a at its polymorphonuclear binding site.  This proteolysis halts 187 
recruitment of C5a-induced granulocytes, further protecting GAS from being overwhelmed 188 
by phagocytes and assists in pharyngeal colonisation (Cleary et al. 2004).  189 
2.1.6 Cysteine protease SpeB 190 
Cysteine protease SpeB is a highly conserved and multi-functional pyrogenic exotoxin 191 
hypothesised to have a role in severe invasive infection and streptococcal toxic shock 192 
syndrome (Collin & Olsén 2001). SpeB is able to cleave human immunoglobulins, including 193 
IgA, IgM, IgD and IgE (Collin & Olsén 2001).  Furthermore, it can cleave vitronectin, 194 
fibronectin and host proteins to compromise host tissue integrity (Kagawa et al. 2009).  It can 195 
also spawn biologically active peptides such as interleukin-1, kinins and histamine (Kagawa 196 
et al. 2000).  Through the degradation of host proteins, research conducted by Barnett et al. 197 
(2013) suggests that a proteolytic SpeB mechanism is utilised by GAS to evade autophagy 198 
and enable replication in the cytosol of host cells.   199 
 200 
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2.2  Genetics including virulence gene control 201 
GAS has been genotyped via M protein typing in an effort to genetically categorise the 202 
species. The famous Lancefield method of M protein typing of emm GAS species determines 203 
the type of opacity factor present through an opacity factor inhibition test.  emm genes are 204 
split up into distinct subfamilies, named from A to E and defined by the sequence differences 205 
at the 3’ end (McGregor et al. 2004).  Classically, A to C emm pattern strains are recognised 206 
as pharyngitis specific, D strains are often isolated from impetigo lesions and E strains are 207 
commonly found at all sites (McGregor et al. 2004).   208 
The size of the GAS genome ranges between 1.85-1.9 Mb, where 1.7 Mb of the GAS genome 209 
is conserved between strains (Wagner & Waldor 2002). Phage transduction is a process 210 
through which DNA can be transferred between a bacterium to a phage.  It known to be an 211 
integral part of GAS survival and development, and phage genomes have the ability to alter 212 
the host bacterial properties in any infection stage.  Specifically, phages can influence 213 
bacterial adhesion, colonisation and invasion, encode bacterial toxins and alter bacterial 214 
susceptibility to antibiotics (Wagner & Waldor 2002).  Beres et al. (2002) found that an 215 
average of 56.2% of unique genes between GAS strains is provided by prophage mediated 216 
gene transfer.   217 
GAS has a formidable arsenal of virulence factors which enables it to persist and cause 218 
infection in a myriad of ways.  The control of virulence factors begins with transcription 219 
regulators which relay information from environmental signals, usually from host-pathogen 220 
interactions.  In short, Mga and RofA-like proteins are the two global regulators which pilot 221 
the cell as per the signals received by two-component signal transduction systems (TCSs) 222 
(Kreikemeyer et al. 2003).  Mga is a conserved response transcriptional activator which plays 223 
a leading role in regulating expression of surface-associated and secreted molecules.  Mga 224 
specifically regulates the M protein, streptococcal collagen-like protein, serum opacity factor, 225 
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C5a peptidase and many other virulence factors essential in host colonisation (Kreikemeyer et 226 
al. 2003). 227 
If environmental conditions become hostile though lack of nutrient supply or host defence 228 
mechanisms, GAS can switch to a stationary growth phase through downregulation of Mga 229 
and upregulation of RofA-like protein (Beckert et al. 2001).   230 
TCSs are not unique to GAS and function in detection and communication of environmental 231 
signals though the transmembrane protein sensor histidine kinase.  Currently, 13 TCSs have 232 
been identified (Kreikemeyer et al. 2003).   Notably, these include ihK/Irr, which plays a role 233 
in host-cell lysis, GAS neutrophil resistance in vitro and in mouse virulence models in vivo 234 
(Voyich et al. 2003).  FasBCA is speculated to regulate expression of extracellular matrix 235 
adhesins to promote high adherence and internalisation rates (Klenk et al. 2005).  SilAB 236 
regulates IL-8 expression of PrtS/ScpC protease, which specialises in degradation of the 237 
murine and human CXC chemokines IL-8, KC and MIP-2 (Hidalgo‐Grass et al. 2006).   238 
The GAS capsule is essential for pathogenesis.  The production of hyaluronic acid, the main 239 
ingredient of the capsule, is controlled by an operon made up of three genes: hasA, hasB and 240 
hasC.  Respectively, these control the production of capsular components hyaluronate 241 
synthase, UDP-glucose dehydrogenase and UDP-glucose pyrophosphorylase, a mechanism 242 
that is likely to be conserved (Albertí et al. 1998).  CsrRS is a regulator of the hyaluronic acid 243 
capsule biosynthetic operon hasABC, and is known to regulate approximately 15% of the 244 
GAS genome (Dalton et al. 2006).    245 
2.3 Nature and spectrum of GAS infections 246 
GAS infection and sequelae encompasses a vast array of disease, including superficial and 247 
invasive infection and associated sequelae (See Table 1).   248 
2.3.1 Common streptococcal throat infection 249 
Strep throat, or acute GAS pharyngitis, makes up approximately one third of all respiratory 250 
tract infections in primary care (Little et al. 2014).   This accounts for approximately 18 251 
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million GP visits and over 7 million visits to paediatricians annually in the US (Carapetis et 252 
al. 2005).  Although major complications are rare, usage of antibiotics has been shown to 253 
prevent suppurative complications such as quinsy, otitis media, sinusitis and cellulitis by at 254 
least 50% (Little et al. 2014; Petersen et al. 2007).  255 
2.3.2 Rheumatic fever and rheumatic heart disease 256 
RF is a delayed sequelae of acute GAS pharyngitis and is characterised by inflammation of 257 
the joints, heart, central nervous system, skin and or subcutaneous nodules (McNamara et al. 258 
2008) (Table 1). The Jones criteria (Burke & Chang 2014) states RF can be diagnosed 259 
through the presence of a preceding GAS infection, plus the presence of two major 260 
manifestations or one major and two minor manifestations of the Jones criteria.  Symptoms of 261 
the Jones criteria mainly include carditis, polyarthritis and Sydenham’s chorea.  Further 262 
research is needed into pathophysiology and potential biomarkers of RF, as the above 263 
symptoms are known to cross over with diseases such as Lyme disease, serum sickness, drug 264 
reactions and post-streptococcal reactive arthritis (Burke & Chang 2014).  265 
The pathogenesis of RF and RHD is poorly understood and two hypotheses currently exist 266 
which attempt to explain the nature of these disease manifestations.  The first hypothesis 267 
proposes molecular mimicry and cross reactivity between sarcomeric heart myosin and 268 
streptococcal antigen M protein.  The second proposes collagen-mediated disease in the 269 
valve.  Tandon et al. (2013) proposes the following inflammatory mechanism: The GAS-m 270 
protein’s N-terminus has been shown to bind to the CB3 region in collagen type IV, which in 271 
turn initiates an antibody response against collagen, resulting in ground substance 272 
inflammation.  However, Cunningham (2014) proposes that both hypotheses function in 273 
tandem.  The majority of autoimmune diseases involve more than one auto-antigen, thus 274 
cardiac myosin and collagen may act as auto-antigens where one precedes the other.  This is 275 
supported by data demonstrating an increase in anti-cardiac-myosin and anti-collagen 276 
antibody in rheumatic carditis (Martins et al. 2008).  277 
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Table 1. Signs/symptoms of GAS superficial and invasive infections, related 
diseases and sequelae 
 
Disease SIGNS AND/OR SYMPTOMS 
Superficial  
Pharyngitis Sore throat, malaise, fever 
Scarlet fever Deep red rash, “strawberry tongue”, exudative pharyngitis 
Impetigo Skin pustules that mature into honey-coloured scabs 
Sequelae  
Acute rheumatic fever Polyarthritis, carditis, rapid and jerky movements, rash, 
subcutaneous nodules 
Rheumatic heart disease Mitral and/or aortic regurgitation with possible stenosis over 
time 
Acute poststreptococcal 
glomerulonephritis 
Oedema, hypertension, urinary sediment abnormalities, 
complement deficiency 
Invasive  
Bacteremia High fever, nausea, vomiting 
Puerperal sepsis Fever, chills, abdominal pain in a pregnant or early 
postpartum woman.   
Cellulitis Acute, tender, erythematous, and swollen area of skin 
Necrotising fasciitis Fever, tender skin lesions, vomiting, diarrhoea, toxaemia, 
tissue destruction 
Streptococcal toxic shock 
syndrome 
High fever, rapid-onset hypotension, accelerated multisystem 
failure 
Adapted from Carapetis et al. (2005) 279 
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2.4 Current treatment options 280 
Antibiotics are the primary treatment for GAS infections.  The advantages of penicillin 281 
include low cost, efficacy and safety.  Other drugs such as cephalosporins, macrolides, 282 
erythromycin and clarithromycin have also proven to be effective and are in use in a clinical 283 
environment (Bisno et al. 2002).   284 
 285 
2.4.1 Antibiotic therapy 286 
A meta-analysis of penicillin vs. cephalosporins treatment was undertaken in the context of 287 
GAS tonsillopharyngitis, and it was found that the cephalosporin cure rate was twice that of 288 
penicillin, making it the superior choice of drug (Casey & Pichichero 2004).  However, 289 
despite the size and number of trials undertaken by Casey and Pichichero, the study has been 290 
criticised for its inconsistencies in control of variables (Bisno 2004).  Notably, out of 35 291 
trials, only 9 were investigator-blinded, 6 were double-blinded, 3 reported dropout rates, 9 292 
provided details of patients signs and symptoms at enrolment and 9 based GAS clearance on 293 
follow-up throat cultures obtained in the optimal 3 to 14 day period after therapy was 294 
completed (Shulman & Gerber 2004). Similar past studies (1953-1993) which retained a high 295 
standard of experiment design failed to find evidence of an increase in penicillin failures 296 
among pharyngitis patients (Markowitz et al. 1993).  Furthermore, the advantage of penicillin 297 
also lies in its price and spectrum:  it is 20 to 30 times cheaper than cephalosporin and has a 298 
smaller target range which reduces the selection pressure and the prevalence of other 299 
antibiotic resistant bacteria (Shulman & Gerber 2004).  300 
Within GAS strains, macrolide antibiotic resistance is beginning to spread through horizontal 301 
transfer of the mef gene.  This is a concern for individuals who are allergic to β–lactam 302 
antibiotics as it equips GAS with a drug efflux pump.   Transposon transfer has already 303 
spread to emm types 1, 2, 3, 4, 9, 12 and 75 (Hadjirin et al. 2014).  Vaccination to provide 304 
long term immunity is essential in worldwide control and elimination of GAS disease.  305 
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2.5 GAS vaccine development  306 
Difficulties in the development of a GAS vaccine include serotype diversity and safety 307 
concerns. For example, GAS molecules with homology to human proteins could potentially 308 
trigger autoimmune sequelae (Kirvan et al. 2003). Additionally, understanding of immune 309 
protection in humans is incomplete and further epidemiological and combination antigen 310 
research is necessary.  Ideally, an effective vaccine would prevent pharyngeal colonisation, 311 
carriage, invasive infection, asymptomatic GAS infection, RF, RHD, APSGN and toxin 312 
mediated complications (Dale et al. 2013). Current categories of vaccine exploration include 313 
the following: anchored cell wall proteins, cell membrane associated and/or secreted and 314 
anchorless vaccine candidates (Table 2).  315 
Vaccine development research is primarily focussed on the highly abundant M protein.  316 
Multi-valent vaccinations are designed to target multiple strains, where 6-valent, 26-valent 317 
and 30-valent GAS vaccines are in clinical or pre-clinical stages (Steer et al. 2013).  Despite 318 
the number of valencies covered, the 30-valent vaccine would geographically only give good 319 
coverage to the US, Canada and Europe, intermediate coverage to Asia and the Middle East 320 
and very poor coverage within Africa and the Pacific.  However, this concern has been 321 
mitigated by research undertaken by Smeesters et al. (2008) whose data proposes that M 322 
protein based vaccines may evoke cross-protective antibodies.  This could broaden the 323 
targeted number of serotypes targeted.  Furthermore, the new 30-valent M protein based 324 
vaccine boasts protection against 98% of known serotypes responsible for pharyngitis and 325 
invasive infections (Dale et al. 2011).    326 
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Table 2. Current vaccination antigens, trials, vaccine types and protein candidates 
Candidates Antigen  Vaccine type/preclinical data Reference 
Cell Wall Anchored Proteins    
M Protein 
 
N-terminal region:  
6-valent, 26-valent and 30-
valent antigen 
 
Multivalent recombinant 
protein/Intramuscular delivery in humans via 
opsonic antibodies 
 
(Dale et al. 2005) (Hu et 
al. 2002) (Dale et al. 
2011) (Kotloff et al. 2004) 
N-terminal peptides linked to 
tetanus toxoid 
Peptide-protein conjugate /Subcutaneous 
delivery in mice via opsonic antibodies 
(Brandt et al. 2000) 
N-terminal peptides linked via 
lipid core peptide 
Lipopeptides: IgG and 
opsonisation/Subcutaneous delivery in mice 
via peptide specific serum 
(Olive et al. 2003) 
Heteropolymer (seven N-
terminal and one C-terminal 
peptides) 
Peptide polymer/Subcutaneous delivery in 
mice via systemic IgG and opsonic 
antibodies 
(Brandt et al. 2000) 
N-terminal Plasminogen- Amino acid residues/subcutaneous delivery (Sanderson-Smith et al. 
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binding group  in quackenbush mice via peptide specific 
serum 
2008) 
C-terminal region:  
Whole C-repeat conserved 
region 
 
Synthetic peptide conjugate/intranasal in 
mice via peptide specific serum 
 
(Bessen & Fischetti 1988) 
Minimal epitope J8/J14/p145 Self-adjuvanting polyacrylic nanoparticulate 
delivery/intranasal delivery in mice via 
peptide specific serum 
(Zaman et al. 2011) 
C-repeat epitope (StreptInCor 
vaccine) 
C-terminal amino acid residues/subcutaneous 
delivery in mice via StreptInCor suspension 
(Guerino et al. 2011) 
Conserved region proteins 
expressed in Lactococcus 
lactis 
C-repeat amino acid residues/nasal and 
subcutaneous delivery in mice via peptide 
specific serum 
(Mannam et al. 2004) 
Fibronectin-Binding Protein A Seven FbaA epitopes co-
administered with five M 
protein fragments 
Recombinant multivalent 
protein/Intraperitoneal delivery in mice via 
peptide specific serum 
(Ma et al. 2014) 
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Protein F1/Streptococcal 
Fibronectin Binding Protein I 
Recombinant H12 co-
administered with M protein 
peptide J14 
Recombinant multivalent 
protein/subcutaneous delivery in mice via 
peptide specific serum 
(Georgousakis et al. 2009) 
Streptococcal Protective 
Antigen 
N-Spa36 epitopes Spa antiserum/intraperitoneal delivery in 
mice 
(Ahmed et al. 2010) (Dale 
et al. 1999) 
Streptococcus pyogenes Cell 
Envelope Proteinase/Spy0416 
Spy0416/SpyCEP epitopes Recombinant CEP protein/Intramuscular 
delivery in mice 
(Turner et al. 2009) 
Cell Membrane Associated 
and/or Secreted GAS 
Candidates 
   
C5a Peptidase C5a Peptidase epitopes 
(functional in GAS and Group 
B Streptococcus (GBS)) 
Recombinant GBS inactive C5a 
peptidase/Subcutaneous delivery in mice  
(Cleary et al. 2004) 
Streptococcal Hemoprotein 
Receptor 
Shr (CFA/IFA Purified Shr/intraperitoneal delivery in mice 
and Shr-expressing Lactococcus lactis 
delivered intranasally in mice.  
(Huang et al. 2011) 
Spe B SpeB catalytic site co- Chimeric SpeB and SpeA/Intramuscular (Ulrich 2008) 
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administered with the binding 
surface of SpeA  
delivery in mice 
Anchorless GAS Candidates    
Streptococcal Immunoglobulin-
Binding Protein 35 
Sib35 epitope rSib35 protein/subcutaneous delivery in mice (Okamoto et al. 2005) 
Arginine 
Deaminase/Streptococcal 
 Acid Glycoprotein 
ADI epitope ADI adjuvanted with CFA/Intraperitoneal 
delivery in mice 
(Henningham et al. 2012) 
Trigger Factor TF epitope TF adjuvanted with CFA/Subcutaneous 
delivery in mice 
(Henningham et al. 2012) 
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2.6 Virus Like Particle (VLP) technology 327 
Vaccines function as a platform for the presentation of an antigen, so that the body can 328 
formulate an immunological memory.  Antigen presentation is a crucial part of vaccine 329 
success and must accurately replicate the inherent immunostimulation of an infection.  VLPs 330 
are constructed from viral structural proteins such as the envelope or capsid which can self-331 
assemble.  VLPs are produced by many viruses including hepatitis B and human 332 
papillomavirus (Zhao et al. 2013).  VLPs must sufficiently interact with innate immune cells, 333 
professional antigen presenting cells (APCs) and adaptive effector/memory cells without 334 
causing host damage (Zhao et al. 2013) to be utilised as a vaccine.  One advantage of VLPs 335 
are that they are able to effectively deliver an antigen to professional APC’s as well as 336 
stimulate both cell-mediated (CMI) and humoral immune (HI) responses.  VLP success has 337 
been demonstrated through protection against of hand-foot-and-mouth disease, influenza, 338 
hepatitis B and human papilloma virus (Bright et al. 2008; Bryan 2007; Chung et al. 2008).   339 
2.6.1 Overview of the use of VLP technology for human diseases 340 
There are many advantages of VLP technology.  VLPs are particulate and have been shown 341 
to illicit immune responses without adjuvant usage making them advantageous for 342 
vaccination as not many adjuvants are available for human use (Fifis et al. 2004).  VLP 343 
Adjuvant properties stem from the small size of the VLP, which allows easy uptake by 344 
dendritic cells for major histocompatibility complex class II (MHC II) cells and subsequent 345 
stimulation of the innate immune response (Grgacic & Anderson 2006).  346 
Traditional aluminium based adjuvants are not well paired with all vaccines as they generate 347 
a Th2 bias.  Th2 humoral responses typically result from infections caused by bacteria and 348 
multicellular pathogens, whilst Th1 cell-mediated responses result from intracellular 349 
infections (Rosenthal et al. 2014).  Th1 responses are directed at inducing CMI and have a 350 
distinct inflammatory bias.  In comparison, Th2 responses reduce inflammation, promote 351 
antibody production and are associated with HI (Goering et al. 2012).  Versatile VLP 352 
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technology can be engineered to induce Th1 or Th2 through particle size control.  Larger 353 
particles encourage increased production of IL-4 for a Th2 response, and smaller particles 354 
result in amplified production of IFN-γ for a Th1 response (Rosenthal et al. 2014).  355 
Licenced VLP vaccines include Recombivax HB® against hepatitis B and Hecolin®, plus 356 
Gardasil® and Cervarix® against HPV (Henningham et al. 2013).  VLPs are most commonly 357 
used to prevent viral pathogens, but there has been evidence of successful delivery of 358 
chimeric bacterial antigens using VLPs (Rosenthal et al. 2014).   359 
2.6.1.1 Generating recombinant chimeras 360 
As mentioned above, GAS-m protein is constituently expressed, highly immunogenic and 361 
promising choice for vaccine development.  The highly conserved C-repeat region within the 362 
M protein contains the p145 peptide, recognised by antibodies of adults living in an 363 
environment with high GAS exposure (see Figure 4). However, challenges for the use of this 364 
peptide in a vaccine include potential molecular mimicry   as the p145 peptide shares an 365 
epitope with the human heart protein myosin (Hayman et al. 1997).  A study by Hayman et 366 
al. (1997) utilising mouse anti-p145 sera determined that the M protein peptides containing 367 
minimal cross-reactivity were J8 and J14.  A follow up study cited by Good and Olive (2003) 368 
showed protection following challenge with GAS and production of opsonic antibodies when 369 
mice were immunised by J8 or J14 in Complete Freund’s Adjuvant (CFA).  Notably, a 370 
vaccine incorporating the conserved J8 M protein is  currently in stage 1 of clinical trials in 371 
Australia (Dale et al. 2013) 372 
 373 
 374 
 375 
 376 
 377 
 378 
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 389 
Past recombinant chimeric platforms include the hepatitis B virus core, woodchuck hepatitis 390 
B virus core, hepatitis B virus S antigen, human papillomavirus, bovine papillomavirus, 391 
human immunodeficiency virus (HIV), simian immunodeficiency virus HIV chimera, duck 392 
hepatitis B virus and hepatitis E virus (Grgacic & Anderson 2006).  In the commercial 393 
setting, VLPs are synthesised through insect and yeast cell-based systems for their ease of 394 
production, cost efficiency, post-translational modifications and adjustable production size.  395 
Bacteria, mammalian and plant cells and cell-free synthesis have been utilised in the 396 
laboratory setting to produce VLPs (Rosenthal et al. 2014).   VLP technology has proven to 397 
be safe, effective, long lasting and cost efficient.  In particular, the HBsAg-S surface protein 398 
is the most common molecule used in VLP technology due to its non-infectious nature and 399 
worldwide licence for use (Netter et al. 2003).    400 
2.6.1.2 Overview of use of HBsAg-S VLPs 401 
HBsAg-S VLPs stimulate both CMI responses and HI responses and hold potential for usage 402 
in dual-vaccination regimens.  Desired genes are often cloned into the HBsAg-S a-403 
determinant region, a highly immunogenic tertiary structure (Netter et al. 2003). The most 404 
Figure 4 GAS-m Protein C-region Peptides    
Research undertaken by Hayman et al. (1997) explored a series of overlapping peptides (p145-J14) 
within the C-region of the GAS-m protein, where Jcon was a non-specific sequence as a control.   
These peptides were recognised by antibodies within adults living in areas of high GAS exposure, 
where the bold peptides are the p145 sequence.  The p145 sequence is flanked by GCN4 sequences, 
which is designed to mimic the α-helical folding of M proteins.   
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recent successful chimeric HBsAg-S vaccine is GlaxoSmithKline’s malaria vaccine 405 
Mosquirix®, currently in phase 3 trials (Wilby et al. 2012).  Similarly, the original hepatitis 406 
B vaccine, first licenced in 1981, continues to markedly reduce incidence of hepatitis B 407 
worldwide.  For example, 18% of Vietnamese children in 1998 were infected with hepatitis 408 
B, compared to a drastic reduction to 2.7% in 2013 (Nguyen et al. 2014).  New HBsAg-S 409 
VLP research has also explored the possibility of incorporating bacterial vaccine epitopes.  410 
Notably, Kotiw et al. (2012) has utilised Helicobacter pylori KatA epitopes in conjunction 411 
with HBsAg-S surface protein.   Results were promising with immunised mice showing 412 
increased bacterial clearance, warranting further exploration in bacterial VLP combination 413 
research.  414 
2.7 The current study proposal 415 
J8, J14 and p145 from the M protein of Streptococcus pyogenes are highly conserved.  416 
Furthermore, these peptides provide an adequate antibody response without resulting in cross 417 
reactivity to human proteins (Dale et al. 2013).  In this study J8, J14 and p145 DNA 418 
sequences will be generated by PCR and cloned into the ‘a’ determinant region of HBsAg-S. 419 
Recombinant HBsAg-S-GASm VLPs will be generated using a mammalian expression 420 
system and assayed for immunogenicity by enzyme-linked immunosorbent assay (ELISA).   421 
2.7.1 Proposed strategy 422 
Indigenous Australians have the highest global RHD and/or RF mortality rate of 30.2 423 
individuals per 100,000 annually (Carapetis et al. 2005).  The purpose of the study is to target 424 
the Australian Indigenous population and developing countries through the development and 425 
evaluation of a HBsAg-S-M protein dual vaccine.  The HBsAg-S surface protein VLP has 426 
proven immunogenic efficacy and safety as numerous licenced vaccines.  Furthermore, the M 427 
protein epitopes J8, J14 and p145 have demonstrated antigenic and safety properties.  428 
PCR generated DNA sequences of J8, J14 and p145 from the M protein of GAS will be 429 
cloned into the ‘a’ determinant region of the HBsAg-SS and transformed into a mammalian 430 
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cell recombinant protein expression system.  Expressed recombinant HBsAg-S-GASm 431 
constructs will be isolated, purified and assayed by WB and ELISA.  Following successful 432 
isolation and purification recombinant molecules will be used to vaccinate BALB/C mice in 433 
GAS challenge studies.   Use of the constructs in challenge models will evaluate their ability 434 
to generate an antibody response though VLP antigen delivery (Figure 5).   435 
 436 
 437 
 438 
 439 
 440 
 441 
 442 
  443 
 444 
 445 
 446 
  447 
GAS epitopes will be 
amplified and cloned 
into the ‘a’ determinant 
region of HBsAg-S 
p145 GAS-m 
protein epitope 
genes 
J8 GAS-m 
protein epitope 
genes 
J14 GAS-m 
protein epitope 
genes 
HBsAg-S-p145, HBsAg-S-J8 
and HBsAg-S-J14 VLPs 
transfected into mammalian 
expression cells 
Expressed VLPs constructs 
isolated and assayed by 
ELISA 
HEK293T 
Figure 5 Proposed Strategy Details 
GAS-m Protein HBsAg-S pcDNA3.1 Vector 
pcDNA3.1:
HBsAg-S 
 
pcDNA3.1:
HBsAg-S 
 
pcDNA3.1:
HBsAg-S 
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Hypotheses 448 
1.  GAS antigenic peptides can be expressed in HBsAg-S VLPs to utilise VLPs as a carrier 449 
molecule for a dual vaccine.  450 
2.  GAS VLPs which are recognised by GAS HBsAg-S sera will be good vaccine candidates 451 
to provide protection against GAS in an animal model. 452 
 453 
 454 
 455 
  456 
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Materials and Methods 457 
 3.0 Bacteria and Plasmids 458 
 459 
Escherichia coli JM109 (Promega) and TOP10 (Life Technologies) was grown in Luria 460 
Bertani (LB) broth or on LB agar containing 100 µg/ml ampicillin.  Incubation of plated and 461 
liquid bacterial cultures was performed at 37°C in a Bioline Thermocube Incubator (Bioline 462 
Alexandria, NSW, Australia), where required shaking was performed at 5 x g.  The 463 
mammalian protein expression vector was pcDNA3.1:HBsAg-S which was kindly provided 464 
by Hans Netter (Monash University, Melbourne, Australia).   465 
3.1 Molecular Analyses  466 
Primers with accompanying forward and reverse sequences are detailed below in Table 3.  467 
Primers were purchased from Invitrogen, and all PCR reactions were carried out in a PTC-468 
100™ Programmable Thermal Controller (MJ Research Inc, Quebec, Canada.).     469 
 470 
 471 
 472 
 473 
 474 
 475 
 476 
 477 
 478 
 479 
 480 
 481 
 482 
 483 
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 484 
 485 
3.2 Amplification of GAS-m Epitopes 486 
Synthesis of GAS-m DNA fragments utilised p145, J8 and J14 forward and reverse primers 487 
as shown in Table 3.  The sequence ‘ACCGGT’ was included as a site for the AgeI restriction 488 
enzyme for ease of ligation of fragments into the pcDNA3.1:HBsAg-S mammalian 489 
expression vector.  Sequences of p145, J8 and J14 were obtained from previous studies by 490 
Hayman et al. (1997).  Expected PCR product sizes for p145, J8 and J14 are 78, 102 and 105 491 
bp respectively.  p145, J8 and J14 forward and reverse primers were used to synthesise the 492 
Applicatio
n 
Template DNA Primer Sequence (5’→ 3’) 
GAS-m 
epitope 
generation 
p145 
 
 
Full 
sequence 
GGAACCGGTCTTCGTCGTGACTTGGACGCATCACG
TGAAGCTAAGAAACAAGTTGAAAAAGCTTTAGAA
ACCGGTTGG 
 Forward 
Primer 
GGAACCGGTCTTCGTCGTGACTTGGACGCATCACG
TGAAGCTAAGAAAC 
 Reverse 
Primer 
CCAACCGGTTTCTAAAGCTTTTTCAACTTGTTTCTT
AGCTTCACGTGATG 
GAS-m 
epitope 
generation 
J8 Full 
sequence 
 
GGCACCGGTCAGGCGGAAGATAAAGTGAAACAGT
CACGTGAAGCTAAGAAACAAGTTGAAAAAGCTTTA
AAACAGCTGGAAGATAAAGTGCAGACCGGTGGC 
  Forward 
Primer 
GGCACCGGTCAGGCGGAAGATAAAGTGAAACAGT
CACGTGAAGCTAAGAAACAAGTTG 
 
  Reverse 
Primer 
GCCACCGGTCTGCACTTTATCTTCCAGCTGTTTTAA
AGCTTTTTCAACTTGTTTCTTAGCTTC 
 
GAS-m 
epitope 
generation 
J14 Full 
sequence 
 
GGCACCGGTAAGCAGGCGGAAGATAAAGTGAAAG
CATCACGTGAAGCTAAGAAACAAGTTGAAAAAGCT
TTAAAACAGCTGGAAGATAAAGTGAAGACCGGTG
GC 
  Forward 
Primer 
GGCACCGGTAAGCAGGCGGAAGATAAAGTGAAAG
CATCACGTGAAGCTAAGAAACAAGTTG 
 
  Reverse 
Primer 
GTGAAGCTAAGAAACAAGTTGAAAAAGCTTTAGTA
CAGCTGGAAGATAAAGTGAAGACCGGTGGC 
Amplificati
on 
HBsAg-
SFwd  
 GTAGAATTCGCCACCATGGAGAACATCACATCAG 
Amplificati
on 
HBsAg-
SRev 
 CTGCGGCCGCTTAAATGTATACCCAAAGAC 
Sequencin
g 
AOX 1 Reverse 
Forward 
GCAAATGGCATTCTGACATCC 
GACTGGTTCCAATTGACAAGC 
Table 3 Sequence of oligonucleotide primers used  
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p145, J8 and J14 GAS-m DNA sequences through PCR.  Three primer pairs were required to 493 
create the fragments as given in Table 3.  Each forward primer 5’ end contained ACCGGT 494 
with three additional N terminal nucleotides to enable restriction digestion with enzyme AgeI-495 
HF (New England Biolabs, Arundel, Queensland, Australia), as seen in Table 3 in bold 496 
lettering.   PCR reactions to generate each fragment contained 5 µl of x10 AccuBuffer 497 
(Bioline), 1 µl of 10 mM dNTPs (Promega, Alexandria, NSW, Australia), 1.5 µl of both 498 
appropriate forward and reverse primers at 20 pmol/µl (Table 3), 1 µl of Accuzyme™ DNA 499 
polymerase (Bioline) and Milli Q water to make reaction volume up to 50 µl.  The PCR was 500 
performed using the following parameters: 95°C for 3 min, followed by 30 cycles of 95°C for 501 
15 s, 56°C for 15 s and 72°C for 15 s.  The resulting PCR products were viewed on a 1% 502 
agarose gel as described in section 3.2.1, followed by purification using the Wizard® SV Gel 503 
and PCR Clean-Up (Promega). 504 
3.3 Agarose Gel Electrophoresis 505 
Gels were prepared as 1% or 2% agarose in 1X TAE containing 0.75% GelRedDNA Stain 506 
(Biotec, Wembley, Australia) for visualisation.  The gel was electrophoresed using a Liberty 507 
(Biokey, California, USA) or Biorad minisub cell GT electrophoresis tank, depending upon 508 
the size of the gel required.  The electrophoresis tank was filled with 1X TAE Buffer.  509 
Samples were loaded for electrophoresis after mixing, in a ratio of 5:1 with 6X blue loading 510 
dye.  5 µl HyperLadder I or V molecular size marker was loaded in a separate well to enable 511 
estimation of the size and concentration of DNA in each sample.  A Power Pac 200 (Bio-Rad, 512 
Gladesville NSW) was used to apply a voltage of 100 V for 60 min per gel.  A Fusion FX5 513 
system (Vilber Lourmat, Eberhardzell, Germany) was used to visualise DNA bands under 514 
UV light in conjunction with Fusion FX7 software (Peqlab, Erlangen, Germany).  When 515 
DNA bands required extraction and purification from agarose gel, the Wizard® SV Gel and 516 
PCR Clean-Up (Promega) system was utilised.  517 
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3.3.1 Wizard® SV Gel and PCR Clean-Up 518 
The Promega (Alexandria, NSW) Wizard® SV Gel and PCR clean-up kit was utilised to 519 
purify PCR products.   The PCR product or the desired DNA band was removed from the 520 
agarose gel and dissolved within 1 µl of membrane binding solution per mg of agarose gel.  521 
The solution was vortexed and incubated at 60°C until fully dissolved and transferred to a 522 
spin column and collection tube assembly for incubation at RT for 1 min.  The assembly was 523 
centrifuged at 30 600 x g in Sigma 1-15 Laboratory Centrifuge for 1 min at RT, the 524 
flowthrough was discarded.  DNA bound to the column membrane was washed with 700 µl 525 
of membrane wash solution and centrifuged further at 30 600 x g for 1 min at RT.  The 526 
flowthrough was discarded and the step was repeated using 500 µl of membrane wash 527 
solution (Promega) and centrifuging at 30 600 x g for 5 min at RT.  After discarding 528 
flowthrough, the spin column was inserted into a sterile 1.5 ml microcentrifuge tube and 50 529 
µl of nuclease free water was pipetted into the spin column.  Following incubation at RT for 530 
1 min, the assembly was centrifuged at 30 600 x g for 1 min at RT.  The flowthrough 531 
containing the DNA of interest was collected in a microcentrifuge tube.  The sample was 532 
electrophoresed on an agarose gel for visualisation.  DNA was stored at -20°C.   533 
3.4 Digestion and Insertion of GAS-m Epitopes into HBsAg-S DNA 534 
sequence 535 
As mentioned in section 3.3.1, the primers used to create the GAS-m fragments contained an 536 
AgeI restriction site to enable insertion into pcDNA3.1:HBsAg-S.  Digestion was achieved 537 
using 5 µl of Cutsmart 1x Buffer (New England Biolabs), 5 units of AgeI HF restriction 538 
enzyme (New England Biolabs) and 50 ng of the appropriate GAS-m fragment made up to 50 539 
µl.  The mixture was then digested for 37°C for 15 min and heated to 65°C for 20 min.  The 540 
pcDNA3.1 vector underwent a similar digestion, where 100 ng of pcDNA3.1:HBsAg-S, 5 µl 541 
of Cutsmart 1x Buffer (New England Biolabs), 5 units of AgeI HF restriction enzyme (New 542 
England Biolabs) and 40 µl of Milli Q Water was combined.  The mixture was digested for 543 
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37°C for 15 min. Following digestion 5 units of Antarctic Phosphatase (New England 544 
Biolabs) and 5 µl of Antarctic Phosphatase buffer (New England Biolabs) was added.  The 545 
mixture was further digested at 37°C for 60 min and heat inactivated at 65°C for 20 min.   546 
Expected PCR product sizes for HBsAg-S:p145, HBsAg-S:J8 and HBsAg-S:J14 were 766, 547 
784 and 787 bps respectively.   548 
3.5 Plasmid Ligation 549 
Ligation was performed at a ratio of 1:3 vector to insert, where pcDNA3.1:HBsAg-S was the 550 
vector and p145, J8 and J14 were the inserts respectively.  The Invitrogen (Mulgrave, 551 
Victoria) rapid ligation protocol was utilised, where 4 µl of 5x ligase reaction buffer 552 
(Invitrogen), 30 fmol of vector DNA, 90 fmol of insert DNA, 1 µl of T4 DNA ligase 553 
(Invitrogen) and Milli Q water up to 20 µl were added to a 1.5 ml microcentrifuge tube.  554 
Contents were centrifuged briefly and incubated at RT for 5 min.     555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
 564 
 565 
 566 
 567 
 568 
 569 
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 570 
3.6 Transformation of Competent Cells  571 
Transformations were undertaken according to One Shot® TOP10 chemically competent 572 
E.coli transformation methods (Invitrogen, Mulgrave, Victoria, Australia).   The appropriate 573 
amount of One Shot® JM109 or TOP10 E. coli was thawed on ice.  5µl of each ligation 574 
reaction was pipetted directly into the vial of competent cells and mixed by tapping gently.  575 
Cells were incubated on ice for 30 min followed by 30 s in a 42°C water bath.  The reaction 576 
was placed back into ice and 250 µl of pre-warmed S.O.C medium (Super Optimal Broth, 577 
details?) was added using sterile technique.  Cells were shaken at 37°C for 1 h and 150 µl of 578 
each transformation was pipetted directly onto labelled LB agar plates containing 1 µg/mL of 579 
Ampicillin and incubated at 37°C overnight.  The ampicillin gene contained in the plasmid 580 
vector was crucial to select potential transformants (Figure 6A).  Colonies were then 581 
repatched onto fresh plates for colony identification.  Possible clones were selected through 582 
PCR performed using the following parameters: 95°C for 1 min 30 s, followed by 30 cycles 583 
of 95°C for 15 s, 55°C for 15 s and 72°C for 1 min 30 s.  AOX1 primers were utilised for 584 
sequencing verification of plasmid preparations believed to contain GAS-m protein fragments 585 
within the HBsAg-S sequence (Table 3).     586 
 587 
3.7 Wizard® Plus SV Minipreps DNA Purification 588 
The Promega (Alexandria, NSW) Wizard® Plus SV Miniprep kit was utilised to purify 589 
plasmid DNA from E. coli.  Preparations of 10 ml of LB containing ampicillin were 590 
inoculated with single colonies of bacteria.  The culture was grown overnight at 37°C with 591 
shaking and centrifuged at 2 400 x g in Sigma 3-15 Laboratory Centrifuge (Shropshire, UK) 592 
for 5 min at RT.  The supernatant was decanted and the pellet resuspended in 250 µl of cell 593 
resuspension solution (Promega). 250 µl of cell lysis solution (Promega) was added to the 594 
suspension and mixed by inversion, 10 µl of alkaline protease solution was then added and 595 
Figure 6 pcDNA3.1 Vector Map 
pcDNA plasmid ap, detailing l cations of the AgeI site, Ampicillin resistance gene and 
mammalian expression promoter.  Taken f om (Xenbase 2014).
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the suspension was inverted four times. The suspension was incubated at RT for 5 min and 596 
350 µl of the neutralisation solution (Promega) was added and the suspension was inverted 597 
four times before centrifugation at 30,000 x g for 10 min at RT.  The supernatant was 598 
transferred to a spin column and collection tube assembly and centrifuged at 30 000 x g for 1 599 
min at RT, where the flowthrough was discarded.  The membrane-bound DNA was washed 600 
with 750 µl of wash solution, added to the spin column and centrifuged at 30 000 x g for 1 601 
minute at RT.  The flowthrough was discarded and the wash step repeated using 250 µl of 602 
wash solution followed by centrifugation at 30 000 x g for 2 min at RT.  The spin column 603 
was re-inserted into a 1.5 ml microcentrifuge tube and 100 µl of nuclease free water was 604 
pipetted directly onto the membrane. The assembly was centrifuged at 30 000 x g for 1 min at 605 
RT.  The flowthrough containing plasmid DNA was harvested and a sample was 606 
electrophoresed on a 1% agarose gel for analysis.  DNA was stored at -20°C.  607 
3.8 DNA Sequencing 608 
The AOX primer (Table 3) was utilised to enable sequencing of the GAS-m constructs within 609 
the HBsAg-S-S sequence of pcDNA3.1.  The reaction mixture for each sequencing PCR 610 
contained 2 µl of Applied Biosystems (Mulgrave, Australia) 5X sequencing buffer , 1 µl of 611 
Big-Dye Terminator sequencing reaction (Applied Biosystems), 3 µl of the appropriate 612 
primer at 1 pmol/µl, 250 ng of plasmid DNA and Milli Q water to make the total reaction 613 
volume 12 µl.  Each reaction was initially heated to 95°C for 2 min, followed by cycling at 614 
95°C for 10 s, 52°C for 5 s and 60°C for 3 min, repeated 25 times.  615 
Following PCR, 72 µl of 70% isopropanol was added and the reaction mixture vortexed and 616 
incubated for 15 min at RT.  It was then centrifuged within a Sigma 1-15 Laboratory 617 
Centrifuge at maximum speed for 30 min at RT.  The supernatant was removed and pellet 618 
was briefly centrifuged to remove the remaining droplet.  The pellet was rinsed with 300 µl 619 
of 70% isopropanol and centrifuged at maximum speed for 5 min.  All liquid was removed 620 
and samples dried in a fume hood for approximately 1 h.  Samples were sent to Queensland 621 
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Institute of Medical Research (QIMR, Brisbane, Australia) for sequencing analysis. Results 622 
were analysed using Bioedit©, a biological sequence alignment editor (Carlsbad, California). 623 
3.9 Wizard® Plus SV Midipreps DNA Purification 624 
The Wizard® Plus Midiprep kit (Promega, Australia) was utilised to purify E. coli plasmid 625 
DNA to the quality and amount required for transfection of mammalian cells.  All solutions 626 
and materials for Wizard® Plus Midiprep kit were obtained from Promega. 100 ml of LB 627 
containing 100 µg/ml ampicillin was inoculated with a colony of freshly grown E. coli 628 
containing the plasmid of interest.  The culture was grown overnight at 37°C with shaking.  629 
Cells were pelleted at 2 400 x g in a Sigma 3-15 Laboratory Centrifuge and resuspended in 3 630 
ml of cell resuspension solution (Promega).  250 µl of Cell lysis solution (Promega) was 631 
added and the suspension inverted 5 times, followed by incubation at RT for 3 min.  632 
Neutralisation solution (Promega) was added, and the suspension inverted a further 10 times.  633 
Lysate was centrifuged at 2 400 x g for 15 min.  A KNF Neuberger (Rowville, Victoria) 634 
vacuum manifold was utilised in conjunction with blue PureYield™ Clearing Columns 635 
(Promega) and white PureYield™ Binding Columns (Promega).  Lysate was pipetted into the 636 
column assembly and a vacuum was applied until lysate passed through the membrane, the 637 
blue column was then discarded. 5 ml of Endotoxin Removal Wash (Promega) was added 638 
and a vacuum applied. 20 ml of Column Wash (Promega) was added and a vacuum applied 639 
once more.  The membrane was dried by applying a vacuum for 30 s and the binding column 640 
was removed from the vacuum manifold.  An Eluator vacuum elution device (Alexandria, 641 
NSW) was fitted to the vacuum manifold assembly to allow collection of DNA into a 1.5 ml 642 
microcentrifuge tube. Finally, DNA was eluted in 600 µl of nuclease free water under a 643 
vacuum to obtain purified plasmid DNA.   644 
3.9.1 HEK293T Cell Culture  645 
Human Embryonic Kidney cells 293T (HEK293T ATCC #CRL-1573) were maintained in 646 
Minimum Essential Media (MEM) culture media (MEM containing 25 mM 4-(2-647 
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hydroxyethyl)-1-piperazineethanesulfonic acid (HEPEs), Glutamax (Gibco®) and 10% fetal 648 
bovine serum (FBS) and incubated in a SANYO Humidified CO2 Incubator (North Sydney, 649 
NSW) at 37°C with 5% CO2.  Cells were passaged regularly to avoid senescence and were 650 
grown in conical flasks.  To passage, cells were viewed under a Leica Leitz DM IL 651 
microscope (North Ryde, NSW) to visually evaluate confluence.  Spent media was discarded, 652 
5 ml of phosphate buffered saline (PBS) was added to the flask and incubated for 2 min 653 
before being discarded; this wash was repeated.  1 ml of Life Technologies 0.05% trypsin 654 
(Mulgrave, Victoria) was added and cells were incubated for <5 min at 37°C with 5% CO2.  655 
After incubation, detached cells were added to 5 ml of MEM culture media to inhibit trypsin 656 
activity.  Cells were centrifuged at 500 x g for 5 min with a 3-15 Laboratory Centrifuge 657 
(Sigma, Osterode am Harz, Germany).  Supernatant was discarded and cells were re-658 
suspended in the MEM culture media and seeded into new culture flasks at a ratio between 659 
1:3 and 1:10.     660 
3.9.2 HEK293T Transfection and Protein Isolation 661 
For transfection cells were seeded at 1.5 x 10
6
 cells/10cm dish in 9 ml of pre-warmed MEM 662 
culture media.  On the following day the media was replaced approximately 2 h prior to 663 
transfection.  A mixture of 16 µg of plasmid DNA, 36 µl of 2M CaCl2 and Milli Q water at a 664 
final volume of 300 µl was combined and quickly added to 300 µl of 2X HEPES buffered 665 
saline (HBS) (containing 10 g/l HEPES; 16 g/l NaCl; 0.74 g/l KCl; 0.27 g/l Na2HPO4.2H2O; 666 
2.0 g/l dextrose). The mixture was vortexed and incubated at 37°C for 3 min before being 667 
added drop wise to the cells with gentle swirling to facilitate mixing.  Cells were incubated at 668 
37°C with 5% CO2.  At 6 days post-transfection, media was taken from the transfection plates 669 
and centrifuged at 690 x g for 10 min in a 3-15 Laboratory Centrifuge (Sigma, Osterode am 670 
Harz, Germany) to remove cellular debris.  Supernatant was gently overlayed onto 2 ml 671 
sucrose in STE (100 mM NaCl, 10 mM Tris at pH 8, 1 mM of EDTA) in Beckman 672 
ultracentrifuge tubes.  Supernatant was centrifuged in a pre-cooled SW41Ti swinging bucket 673 
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rotor at 10°C and 172 700 x g for 4 hours.  The resulting supernatant was discarded and the 674 
pellet resuspended in 200 µl of 1X HBS over two nights, followed by sonication using an 675 
Ultrasonic Cleaning bath (Unisonics, Brookvale, NSW) for 5 x 30 s intervals.  The 676 
supernatant used in subsequent testing by ELISA.  677 
3.9.3 ELISA 678 
Two ELISA tests were undertaken to detect both the presence of my GAS M proteins and 679 
HBsAg-s VLPs though usage of J8 and HBsAg-s sera.  Proteins were coated as a serial 680 
dilution in triplicate wells and tested with polyvalent antibody. Negative and positive control 681 
samples were included within these tests. The ‘mock’ sample referred to a protein harvest 682 
where no DNA was transfected into the HEK293T cells, and a ‘no protein’ sample was also 683 
coated to control discrepancies in the ELISA test. Positive controls included Heat-killed GAS 684 
bacteria and Engerix B (the current Hepatitis B VLP vaccine).   685 
High-binding 96 well Greiner Bio one plates were coated with 5 µl of protein in carbonate 686 
coating buffer (0.1 M NaHCO3 at pH 9.6), in 100µl of coating buffer per well. The plate was 687 
sealed and incubated over night at 4°C.  The following day, plates were washed twice with 688 
PBST (0.05% Phosphate Buffered Saline with Tween20) which contains 3.2 mM Na2HPO4, 689 
0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl and 0.05% Tween
®
 20.  100µl of blocking 690 
buffer (2% skim milk in PBS) was added to each well and incubated for 1.5 h.  The plate was 691 
washed twice with PBST and 100µl of serially diluted primary rabbit sera (anti-HBsAg-S or 692 
J8 sera). 1% skim in PBS was added per well and incubated at for 1 h.  The plate was washed 693 
four times with PBST, and 100µl of anti-rabbit conjugated antibody (Sigma) diluted at 694 
1:3,000 in 1% skim in PBS was added per well and incubated at RT for 1 h.  The plate was 695 
washed six times with PBST and 100µl of TMB was added to each well.  After development 696 
in a dimly-lit environment, the reaction was stopped with the addition of 50µl of 2M H2SO4.  697 
Absorbance was read at 450 nm with a 200rt Biochrom Zenyth Anthos ELISA machine 698 
(Cambridge, UK).   699 
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Results 700 
4.0 GAS-m epitope Amplification 701 
The p145, J8 and J14 DNA sequences were generated by PCR amplification.  Primers were 702 
designed with an overlap of approximately 20 base pairs between forward and reverse 703 
primers.  AgeI restriction enzyme sites were also included on each end for insertion into the 704 
HBsAg sequence, an overhang of 3 nucleotides was included to enable better efficiency of 705 
restriction digestion downstream (Figure 7A).   Generated p145, J8 and J14 GAS-m 706 
fragments had expected sizes of 78 bp, 102 bp and 105 bp respectively and these sizes were 707 
confirmed through agarose gel visualisation (Figure 7B).  708 
 709 
 710 
 711 
 712 
 713 
 714 
 715 
 716 
 717 
 718 
 719 
 720 
4.1 GAS-m Fragment Insertion into HBsAg 721 
HBsAg-s and pcDNA3.1 were digested and ligated first in readiness for GAS-m epitope 722 
insertion into the ‘a’ determinant region of HBsAg-s. Firstly, pcDNA3.1:HBsAg-s post 723 
Figure 7 Primer design and matching agarose gel fragments 
A. Primer design for generation of p145, J8 and J14, designed to include resitriction 
enzyme sites for AgeI restriction enzyme and synthesised with forward and reverse long 
primers.  B. 2% agarose gel depicting the amplified p145, J8 and J14 DNA respectively in 
lanes 1, 2 and 3.  Sizes depicted approximately mirror the expected sizes of 78 bp, 102 bp 
and 105 bp. Smear above bands is present as DNA had not been purified as detailed in 
section 3.2.   
 
A 
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B 
1          2           3 
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ligation vector was transformed into JM1091 TOP10 Escherichia coli (Promega) for 724 
selection of positive uptake through PCR screen as described in section 3.3.  Plasmid was 725 
visualised on agarose gel (Figure 7) and sequence integrity was confirmed through 726 
sequencing.  GAS-m constructs p145, J8 and J14 fragments were inserted into the ‘a’ 727 
determinant of the HBsAg-s within pcDNA3.1 through AgeI digestion followed by ligation.  728 
Expected product output size was 766 bp, 784 bp and 787 bp respectively for p145, J8 and 729 
J14 fragments selectively amplified from within pcDNA3.1:HBsAg (Figure 7).   730 
 731 
 732 
 733 
 734 
 735 
 736 
 737 
 738 
 739 
 740 
 741 
 742 
 743 
 744 
 745 
 746 
 747 
 748 
 749 
Figure 8 1% Agarose gel of amplified DNA from a colony PCR screen 
demonstrating insertion of GAS-m fragments into the ‘a’ determinant 
region of HBsAg 
Wells contain 1 µl and 0.4 µl of each HBsAg:p145 (lanes 1-2), HBsAg:J8 (lanes 3-4) and 
HBsAg:J14 (lanes 5-6) PCR products respectively. These were amplified through PCR 
utilising HBsAg forward primers and HBsAg reverse primers.  
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4.2 PVLP55 Vector Insertion 750 
 751 
 752 
 753 
 754 
 755 
 756 
 757 
 758 
 759 
Figure 9 Agarose gel of pcDNA3.1 containing HBsAg:GAS-m fragments   760 
Plasmids were purified from E. coli utilising the midiprep technique as described in section 761 
3.2.  Wells 1 and 2 contain pcDNA3.1:HBsAg-s:p145, 3 and 4 contain pcDNA3.1:HBsAg-762 
s:J8 and 5 and 6 contain pcDNA3.1:HBsAg-s:J14, where each sample was run on the gel in 763 
0.4 µl (lanes 1, 3 and 5) and 1 µl (lanes 2, 4 and 6).  764 
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4.3 DNA Sequence Analysis  767 
Sequencing analysis was carried out to verify correct insertion of the GAS-m epitopes into 768 
the HBsAg sequence.  Sequencing results from the pcDNA3.1:HBsAg:p145 plasmid 769 
confirmed that the inserted p145 sequence is 60 base pairs in length, in the correct orientation 770 
and sequence integrity was maintained (Figure 9).  Sequencing results for J8 and J14 inserts 771 
were not completed.  772 
 773 
 774 
 775 
  776 
 777 
 778 
 779 
 780 
 781 
 782 
 783 
 784 
 785 
 786 
 787 
 788 
 789 
 790 
 791 
 792 
 793 
 794 
Figure 10 Chromatogram of pcDNA3.1:HBsAg-s:p145 sequencing 
Sequencing results for the region covering the p145 insert are displayed alongside the 
matching original reverse compliment sequences for comparison.  
 
 
 
p145 
TTCTAAAGCTTTTTCAA C T T 
GTTTCTTAGCTTCACGTGATGCGTCCAAGTCACGACGAA 
Original reverse complement sequence 
Sequencing results 
3’ 
bp bp 
5’ 
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 4.4 Detection of HBsAg:GAS:m VLPs by ELISA 795 
ELISA was undertaken to confirm expression of HBsAg VLP and HBsAg:GAS:m VLP 796 
constructs. These proteins have been referred to as VLP, VLP:p145, VLP:J8 and VLP:J14 797 
throughout this study.  The ELISA plates were pre coated with protein in carbonate coating 798 
buffer, and serial dilutions of HBsAg and J8 sera polyvalent rabbit sera were performed in 799 
triplicate. Following incubation with the secondary HRP antibody and the addition of TMB 800 
substrate absorbance was measured at 450 nm (Figure 10).  Titres of VLP:p145 from both 801 
HBsAg and J8 sera tests were similar to the heat-killed GAS positive control and higher than 802 
the VLP expression control and Engerix B.  This indicates that >20 µg/mL of VLP:p145 803 
resulted from protein expression. Engerix B is the current Hepatitis B vaccine and is a 804 
formulation containing HBsAg VLPs at 20 µg/mL. However, analysis of the VLP:J8 and 805 
VLP:J14 protein samples resulted in a reading lower than the mock (no transfection) negative 806 
control.  807 
 808 
 809 
 810 
 811 
 812 
 813 
 814 
 815 
 816 
 817 
 818 
 819 
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 820 
 821 
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 824 
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 827 
  828 
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Figure 11 Detection of VLP:p145, VLP:J8 and VLP:J14 by ELISA 
Serial dilutions of primary J8 serum (A) or HBsAg-s serum (B) were utilised where the graph 
displays mean ± standard error for triplicate wells at 450 nm absorbance.  Primary sera dilution 
refers to the ratio at which the protein was diluted.  High titres of VLP:p145 were obtained for 
both J8 and HBsAg-s sera in comparison to the positive controls. Low titres of VLP:J8 and 
VLP:J14 were obtained in comparison to the negative controls.  
A 
B 
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Discussion 847 
GAS is responsible for a substantial global disease burden with an estimated 18.1 million 848 
individuals currently suffering disease due to GAS infection and sequelae (Carapetis et al. 849 
2005).  Despite GAS susceptibility to penicillin, the disease burden has not been shown to 850 
decrease and effective treatment of sequelae such as RHD can require monthly penicillin 851 
injections over many years (Gerber et al. 2009).  Preventative measures such as improved 852 
living conditions and vaccination are the superior solutions in terms of reducing mortality, 853 
morbidity and economic costs, including within the developed world.  854 
In this study, GAS M protein epitopes p145, J8 and J14 were amplified by PCR through 855 
custom primers and inserted into the ‘a’ determinant region of HBsAg within a mammalian 856 
expression vector.   857 
Sequencing results displayed successful insertion of the p145 gene (Figure 9).  Sequencing 858 
results for HBsAg:J8 and HBsAg:J14 fragments are incomplete, however no errors have been 859 
observed in preliminary sequence data to date.  Correct sequencing data is of paramount 860 
importance as errors such as double or backwards inserts can occur in recombinant DNA 861 
manipulation.  The ‘a’ determinant region of HBsAg-s is located within a double-looped 862 
structure where one 22 nm particle contains about 100 HBsAg-s molecules.  Incorrect 863 
insertion in this area could result in unfavourable assembly of proteins for antibody 864 
recognition (Netter et al. 2001).    As well as sequencing results, DNA purification techniques 865 
can also be employed to reach a quality DNA output and remove short primers, 866 
unincorporated dNTPs, enzymes, short failed PCR products and salts from PCR reactions.  867 
Techniques described in sections 3.2.2, 3.2.4 and 3.2.5 of DNA purification and clean up 868 
assisted in this process.  Netter et al. (2001) undertook a similar study utilising HBsAg-s 869 
VLPs where proteins were purified through a 20% sucrose cushion followed by a CsCl 870 
density gradient, which was further measured by the Prism HBsAg assay.  Examination by 871 
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electron microscopy was also performed and compared with wild type HBsAg.  Further 872 
development on this study could be conducted by mirroring Netter’s purification methods.  873 
Further techniques such as hydroxyapatite chromatography for the purification of plasmid 874 
DNA and affinity tagging for protein purification could be considered (Hilbrig & Freitag 875 
2012; Young et al. 2012).  876 
Protein expression was achieved using HEK293 cells.  A similar study, undertaken by Kotiw 877 
et al. (2012), utilised epitopes from the H. pylori KatA gene inserted into HBsAg-s. In this 878 
study, VLPs were expressed using the HuH7 hepatocellular carcinoma cell line for use in 879 
animal vaccination models. Sufficient yield was obtained for animal model testing and 880 
HBsAg-s conformation was confirmed through electron micrographs.  Furthermore, this 881 
method of VLP expression has also shown success in studies by Netter et al. (2003) with 882 
Hepatitis C VLPs and Schumacher et al. (2007) in tumor therapy VLPs.  This study, 883 
however, utilised HEK293 cells, a predominant cell line used for transient expression of 884 
recombinant proteins, where a foreign gene is expressed for a period of time but not 885 
integrated into the genome.  The HEK293 cell line has the clear advantage of rapid 886 
production for usage within a time-restricted study (Geisse & Fux 2009).    887 
ELISA testing was undertaken to confirm expression and measure antigenic recognition of 888 
VLP constructs through serial dilution of HBsAg and J8 sera.  Results indicated a high 889 
VLP:p145 yield for both J8 and HBsAg sera tests.  Similar results of the positive control 890 
heat-killed GAS and standard VLP controls in comparison to VLP:p145 were obtained with 891 
an estimated yield of 20 µg/mL (Figure 10A and 10B), indicating immunogenicity.  Studies 892 
by Wurm et al.  (2004)  indicate that baseline values of 20-40 µg/mL yields can be obtained 893 
at a specific productivity of 1-4pg/cell/day using HEK293 cells, suggesting that VLP:p145 894 
yields within this study are on par with research standards. Within both primary sera tests, 895 
VLP:J8 and VLP:J14 proteins were detected at similar or lower titres in comparison to the 896 
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negative controls.  Low titres of VLP:J8 and VLP:J14 indicate that either the original DNA 897 
sequence was incorrect or the correct VLP was unfavourable for antibody detection. The 898 
presence of an incorrect DNA sequence is possible as it is still unverified by sequencing 899 
results.  However, if the latter conclusion is correct then this would suggest that placement of 900 
these GAS:m genes for use within VLP may be unsuitable due to incompatibility.  Similar 901 
findings by Kotiw et al. (2012) and Netter et al. (2003) support this conclusion, where data 902 
has suggested that interference may occur when the HBsAg-s ‘a’ determinant is disrupted by 903 
foreign sequences.  This could be due to minor epitopes remaining within the ‘a’ determinant 904 
or elsewhere in the HBsAg molecule, misfolding or unstable expression of HBsAg-s proteins.    905 
ELISA testing within this study is a potential limitation as actual expression level may vary 906 
as peptides have been inserted into the ‘a’ determinant region which is highly antigenic.  907 
Further protein verification work and higher yields are required before the project could be 908 
continued.  This study is further limited by the lack of protein purification and SDS-PAGE 909 
results, which could further indicate protein quality.   910 
To increase protein expression yields for animal studies a yeast expression system could be 911 
considered.  Yeast systems utilising Saccharomyces cerevisiae in the development and 912 
production of the Hepatitis B vaccine were successful obtaining high yields and successfully 913 
demonstrated protection in grivet monkeys (McAleer et al. 1984). Yeast expression systems 914 
are favourable as they can obtain high protein yields of 1000 µg/mL (Young & Robinson 915 
2014).  Additionally, yeast systems hold the advantage of being single cells with fast growth 916 
capabilities as well as possessing eukaryotic abilities such as secretory pathways leading to 917 
correct protein processing (Porro et al. 2005).   918 
Significance 919 
VLPs have a number of advantages as a vaccine as they are particulate in nature, safe, stable 920 
and able to carry foreign epitopes.  Particulate vaccines are advantageous as they can be 921 
efficiently taken up by APCs, this enables the VLP to act as an adjuvant and may mean that 922 
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other adjuvants are not required within the vaccine preparation. VLPs are non-infectious, 923 
non-replicating and have higher stability than soluble antigens in extreme environmental 924 
conditions, this makes VLPs favourable for use in developing countries (Zhao et al. 2013). 925 
VLP and foreign antigen compatibility make recombinant proteins potentially useful for 926 
usage within dual vaccine regimens.  Within this study, peptides of GAS M protein were 927 
inserted into the ‘a’ determinant region of HBsAg-s sequence which is highly immunogenic 928 
(Netter et al. 2003; Vietheer et al. 2007). 929 
Approximately 20 GAS vaccine prototypes have been created across the spectrum of GAS 930 
cell wall and secreted proteins, yet few have progressed to clinical trials.  Evidence has 931 
shown that there is a biological feasibility for such a vaccine to exist.  For example, GAS 932 
pharyngeal studies undertaken in the 1970’s successfully demonstrated protection against 933 
challenge with a homologous strain of GAS after immunisation with purified M proteins 934 
(Polly et al. 1975).  Preclinical murine studies have demonstrated protection against 935 
challenge infections when vaccinated with purified M proteins (Dale et al. 2011; Guerino et 936 
al. 2011). Furthermore, patterns of GAS infection in school aged children who are 937 
repetitively exposed to GAS indicate that a threshold level of protective immunity can be 938 
achieved (Martin et al. 2004).  939 
Despite a long record of research in GAS vaccine development, a protective/acceptable 940 
vaccine is not yet in the foreseeable future.  The World Health Organisation’s roadmap for 941 
GAS vaccine development outlines past and present research for future developments is a 942 
step forward in collaboration of multi-disciplinary consensus in vaccine licensure, but many 943 
challenges are still present (Dale et al. 2013). Remaining challenges include safety concerns 944 
about the theoretical risk of autoimmune reactions and a necessity for further understanding 945 
of the basis for immunological protection in humans.  For example, a greater understanding 946 
of the contributions of non-M type-specific antigens in inducing protective immunity, 947 
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immune protection against GAS skin infection and the role of T-cell immunity are necessary 948 
(WHO 2014). 949 
Suitable GAS peptides intended for vaccination must be conserved throughout GAS 950 
serotypes and free of molecular mimicry to human host antigens.  To date, the most 951 
successful peptides to overcome these challenges have arisen from the M protein.  Early 952 
studies utilising whole M protein resulted in the development of RF-like symptoms, however, 953 
refined attempts such as StreptInCor, J8 and J14 minimal epitope vaccines and the 30-valent 954 
vaccine have shown promising results in animal and clinical trials (Dale et al. 2011; Guerino 955 
et al. 2011; Massell et al. 1968). However, serotype-specific prototypes such as these have 956 
been criticised due to low coverage of strains prevalent in developing countries (Steer et al. 957 
2009).  Thus, the previous 26-valent vaccine which had progressed to Phase II clinical trials 958 
in adult human volunteers was re-worked into a 30-valent vaccine to allow greater coverage 959 
in the Asia-Pacific region. Criticism regarding coverage has been met with a counter-960 
argument in the light of evidence suggesting cross-protection between emm-types may be 961 
inferred by the re-developed 30-valent vaccine (Sanderson-Smith et al. 2014).  However, 962 
high valency vaccines such as these may incur a higher production costs making the vaccine 963 
prohibitive for widespread use.  Both the 30-valent and the minimal epitope J8 vaccine are 964 
anticipated to begin phase I trials within adult volunteers as of 2014 (WHO 2014).  The main 965 
advantage of the 30-valent vaccine lies in the wide coverage through utilisation of fused 966 
recombinant peptides from the N-terminal section of M protein. However, conserved M 967 
protein vaccines such as StreptInCor and the minimal epitope J8 and J14 vaccines have the 968 
greater advantage of consisting of single antigens, lessening the chance of a potential 969 
autoimmune reaction (Batzloff et al. 2003; Guerino et al. 2011).  970 
Use of virus-like particles in conjunction with minimal epitope J8 and J14 vaccines are likely 971 
to broaden the immune response, making combination vaccines are a more viable approach in 972 
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the long term. Despite the multitude of functional GAS vaccine candidates, no commercial 973 
vaccine is yet available.  It is likely that there is reluctance by large pharmaceutical 974 
companies to invest in clinical development of GAS.  Questionable markets for a GAS 975 
vaccine in affluent countries and the challenges mentioned previously may amount to an 976 
adverse commercial risk (WHO 2014).  A combination GAS/Hepatitis B vaccine may present 977 
a more effective and reliable investment for usage within developed and developing countries 978 
alike.  Furthermore, worldwide Hepatitis B vaccination is part of the WHO’s primary 979 
prevention and control framework for global action (WHO 2012). A successful vaccine such 980 
as this could allow smarter investing, improve quality of life and reduce mortality across 981 
developing and developed countries alike.  982 
Future Directions 983 
A combination vaccine for both GAS and Hepatitis B could be an important piece of the 984 
puzzle within global health, and this study had success in the synthesis of VLP:p145.   985 
To progress this study it is essential to verify the sequencing of VLP:J8 and VLP:J14, to 986 
confirm correct insertion orientation of GAS:m fragments within the HBsAg ‘a’ determinant 987 
region.  Further protein analysis such as SDS-PAGE and western blot and other testing to 988 
verify protein purity and configuration could be conducted.   989 
Proof-of-concept animal studies are essential to evaluating the success of this project.  990 
Isolated and purified vaccine candidates would be evaluated in GAS challenge studies.   Mice 991 
would be vaccinated with recombinant VLPs followed by intranasal challenge with GAS 992 
mice would then be euthanized and examined for an immunological response.  Vaccinated 993 
mice serum would be assayed for a specific antibody.  GAS load in pharyngeal tissue would 994 
be determined by culture and histology 4 days post bacterial challenge.  Generation of this 995 
data using would evaluate the ability of GAS:m proteins to generate an antibody response and 996 
protection from GAS infection when delivered as a dual vaccine within the HBsAg VLP.    997 
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 Conclusion 999 
A successful GAS vaccine has the potential to save over 500,000 premature deaths annually, 1000 
greatly improve quality of life and reduce the economic burden of common childhood 1001 
diseases caused by GAS (Carapetis et al. 2005).    1002 
ELISA assays showed that GAS antigenic peptides can be expressed in HBsAg VLPs for use 1003 
as a dual vaccine.  Specifically, from preliminary results VLP:p145 obtained high protein 1004 
titres.  Further testing of these vaccine candidates still needs to occur and use of proof-of-1005 
concept murine challenge models will be essential in assessing their efficacy.  GAS vaccines 1006 
are possible, but not in the foreseeable future despite a long history of developments.  1007 
Incorporation of GAS:m peptides into a dual or combination vaccine may offer a more 1008 
appealing solution for widespread GAS protection across developed and developing countries 1009 
alike.   1010 
  1011 
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